pharma · Obesity · Obesity With Diabetes · KLRA
Kailera Therapeutics
Kailera Therapeutics is a pharma organization headquartered in Waltham, USA. It trades on NYSE under ticker KLRA. Primary therapeutic focus areas include Obesity, Obesity With Diabetes. NovaPharmaNews links 7 clinical pr
Company details
- Status
- Public
- HQ
- Waltham, USA
- Founded
- 2024
- Employees
- 153
- Programs
- 7
- Drugs
- 3
- Patents
- 0
Quick answer
Kailera Therapeutics is a pharma organization headquartered in Waltham, USA. It trades on NYSE under ticker KLRA. Primary therapeutic focus areas include Obesity, Obesity With Diabetes. NovaPharmaNews links 7 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (5), phase 2 (1), phase 1 (1).
Company snapshot
Kailera Therapeutics (Kailera) is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity. Kailera’s most advanced program, KAI-9531 (being developed in China as HRS9531), is an injectable GLP-1/GIP receptor dual agonist that demonstrated positive clinical trial results in obesity in China. The Company is also advancin
- 7 active pipeline program(s) linked via ClinicalTrials.gov.
- 7 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for Kailera Therapeutics. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
Kailera's Triple-G Drug: A Potential Game-Changer in Pharma
- trial_data
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Data at ADA 2026
Recent coverage
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Data at ADA 2026
Hengrui Pharma and Kailera Therapeutics presented clinical data for oral ribupatide (HRS9531) at the ADA 2026 conference. The Phase 2 trial showed positive weight loss results, and the partners plan to advance the asset into two new trials.
Kailera's Triple-G Drug: A Potential Game-Changer in Pharma
Kailera's triple-G drug showed powerful efficacy in early trials announced May 27, 2026. This catalyst analysis outlines implications for pharma business development, regulatory teams, and investors.
Top assets
Lead pipeline drugs
- Marketed / approved
- approved
- Marketed / approved
- Phase 3
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Momentum
Proprietary activity score for Kailera Therapeutics.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Recent activity
Latest pipeline, patent, and corporate events for Kailera Therapeutics.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Kailera Therapeutics?
-
Is Kailera Therapeutics publicly traded?
-
What drugs does Kailera Therapeutics develop or market?
-
What are the latest developments for Kailera Therapeutics?
-
What therapeutic areas does Kailera Therapeutics focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.